Andere Kunden interessierten sich auch für
![The New Health Bioeconomy]( "The New Health Bioeconomy")
The New Health Bioeconomy37,99 €![Unveiling the Powerhouse: Bacillus subtilis - From Food to Modern Medicine]( "Unveiling the Powerhouse: Bacillus subtilis - From Food to Modern Medicine")
Unveiling the Powerhouse: Bacillus subtilis - From Food to Modern Medicine28,56 €![Printing the Future of Medicine: 3D Printing for Personalized Drug Delivery]( "Printing the Future of Medicine: 3D Printing for Personalized Drug Delivery")
Printing the Future of Medicine: 3D Printing for Personalized Drug Delivery30,99 €![Trends in EU Health Care Systems]( "Trends in EU Health Care Systems")
Trends in EU Health Care Systems74,99 €![Identification and discussion of the effect of emerging issues on the hospitality industry following the EU Referendum result in June 2016]( "Identification and discussion of the effect of emerging issues on the hospitality industry following the EU Referendum result in June 2016")
Identification and discussion of the effect of emerging issues on the hospitality industry following the EU Referendum result in June 201615,95 €![Datenschutzrechtliche Rahmenbedingungen medizinischer Forschung - Vorgaben der EU-Datenschutz-Grundverordnung und national geltender Gesetze]( "Datenschutzrechtliche Rahmenbedingungen medizinischer Forschung - Vorgaben der EU-Datenschutz-Grundverordnung und national geltender Gesetze")
Datenschutzrechtliche Rahmenbedingungen medizinischer Forschung - Vorgaben der EU-Datenschutz-Grundverordnung und national geltender Gesetze59,95 €![Green and Sustainable Pharmacy]( "Green and Sustainable Pharmacy")
Green and Sustainable Pharmacy110,99 €
The regulation on European Health Technology Assessment (EU HTA) entered into force on 11 January 2022 and will apply from 12 January 2025. It introduces joint clinical assessments and joint scientific consultations at the European level for new health technologies, including pharmaceuticals and medical devices. While market access, pricing and reimbursement will continue to be the responsibility of EU member states, EU HTA will nevertheless have an immense impact on these national market access activities. This book serves as a practical guide designed to help developers of pharmaceuticals prepare for the upcoming EU HTA process.